FDA Alert

FDA Mandates Sweeping Labeling Changes for All Opioid Pain Medications to Highlight Long-Term Use Risks

Kate Young

In May, following a joint meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee, the FDA required new information for drug labeling of all opioid pain medications.

“The death of almost one million Americans during the opioid epidemic has been one of the cardinal failures of the public health establishment,” Marty Makary, MD, MPH, FDA commissioner, said in an FDA press release.

The following changes were outlined by the FDA release:

  • The labeling now includes new data from two FDA-required observational studies (PMRs 3033-1 and 3033-2) that quantify the risks of long-term opioid use, including misuse, abuse, addiction, and both fatal and non-fatal overdose.
  • The FDA is requiring clearer language in labeling to highlight that higher opioid doses are associated with greater risks, and that these risks persist over time.
  • Labeling language that could be interpreted as supporting indefinite use of opioid medications for pain management has been removed.
  • The revised labels reinforce that extended-release or long-acting opioids should be used only for severe, persistent pain that cannot be managed adequately with other treatments, including immediate-release opioids.
  • The labeling warns against abruptly discontinuing opioid medications in physically dependent patients due to the risk of withdrawal symptoms, uncontrolled pain, and suicide.
  • Updated labels now include information on opioid overdose reversal agents such as naloxone and nalmefene and recommend that health care professionals discuss these options with all patients prescribed opioids.
  • Warnings about drug interactions have been expanded to include enhanced cautions about combining opioids with central nervous system depressants, specifically adding gabapentinoids to the list of concerning combinations.
  • The FDA has added information about toxic leukoencephalopathy, a serious brain condition that may result from opioid overdose, to the safety labeling.
  • The labeling now includes updated warnings regarding opioid-related complications
  • affecting the esophagus and other aspects of digestive health.
  • Manufacturers are required to submit revised labeling to the FDA within 30 days of receiving notification of these required changes.

In addition to these labeling changes, health care providers are advised to prescribe the lowest effective dose of immediate-release opioids for the shortest duration necessary when alternative treatment options are insufficient. Prescribers are also encouraged to regularly reassess the benefit-risk balance for patients who have been taking opioids for more than a few days. The FDA has also mandated a new randomized, controlled clinical trial to further evaluate the long-term efficacy and risks of opioid therapy.

References:

  1. FDA is requiring opioid pain medicine manufacturers to update prescribing information regarding long-term use: Drug safety communication. https://www.fda.gov/safety/medical-product-safety-information/fda-requiring-opioid-pain-medicine-manufacturers-update-prescribing-information-regarding-long-term?utm_medium=email&utm_source=govdelivery. Published August 1, 2025. Accessed August 8, 2025.
  2. FDA requires major changes to opioid pain medication labeling to emphasize risks. https://www.fda.gov/news-events/press-announcements/fda-requires-major-changes-opioid-pain-medication-labeling-emphasize-risks?utm_medium=email&utm_source=govdelivery. Published July 31, 2025. Accessed August 8, 2025.